Down 55%, Should You Buy the Dip on Pfizer? Pfizer is a pharmaceutical industry giant facing normal pharmaceutical industry headwinds; it will survive.
Is Pfizer Stock a Buy After This $10 Billion Acquisition? The company has been on an acquisition spree for years, and this one may be the most important yet.
Deal Dispatch: Warner Bros., Bill.com, C3 AI—Key Auctions And Buyouts Shake The Market Paramount, Comcast, Netflix, Clearlake, Blackstone, and others drive major M&A activity. On the sell side are WBD, Bill.com and TuneIn.
Ozempic Maker Novo Nordisk Faces Board Shakeup Novo Nordisk faces board changes, investor friction and bold M&A moves as leadership pushes to regain momentum in the obesity drug market.
Why Is Everyone Talking About Novo Nordisk Stock? There is hardly a dull moment for the drugmaker these days.
Pfizer CEO Sees Metsera’s Drugs Hit Market As Early As 2028 After Completing Acquisition: Report CEO Albert Bourla told Yahoo Finance that the acquisition of GLP-1 maker Metsera is part of the company's "right to win" in the obesity drug game.
Pfizer Seeks To Exit BioNTech Investment After Lucrative Covid Vaccine Run Pfizer plans to sell its remaining BioNTech stake through a $508 million block trade, ending a profitable Covid-19 vaccine partnership.
Should You Forget Pfizer and Buy This Magnificent Drug Stock Instead? Pfizer has a huge dividend yield and a high payout ratio compared to Merck, which could make Merck the more attractive dividend stock.
Why Metsera's Share Price Is Plummeting This Week The biotech start-up's stock had been rising rapidly in 2025.
Novo Nordisk Rises Despite Metsera Loss, Slashes Wegovy Price In India Novo Nordisk shares are trading higher on Tuesday. The company recently lost its bidding war for Metsera Inc.
Where Will Pfizer Be in 3 Years? Pfizer is working to deal with typical business issues in the drug space, but its attempt at a solution has become very complicated.
Who's Winning the Intense Battle to Rule the White-Hot GLP-1 Drug Market? Three large pharmaceutical makers are jockeying for position in the rapidly expanding market for GLP-1 drugs.
Shutdown Deal Breathes New Life Into Wall Street The prospect of a quick end to the US government shutdown has rekindled investor confidence. Tech rebounds, semiconductors sprint ahead, and insurers feel political pressure building. Meanwhile, all eyes shift toward the last major earnings report of the season: Nvidia.
Metsera Tumbles After The Pfizer-Novo Buyout Battle Ends At $10 Billion The final bid, at $10 billion, is expected to wrap up after Nov. 13 with the next shareholders' vote.
Monday's pre-market session: top gainers and losers The US market session of Monday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.
Novo Nordisk Loses Metsera Bidding War To Pfizer — But Retail Traders Aren’t Losing Faith Novo investors on Stocktwits praised new CEO Mike Doustdar as “dynamic,” saying they remain confident in Novo’s long-term obesity and diabetes pipeline despite short-term setbacks.
